maintenance dosing semaglutide GLP-1 Medications Explained: Dosage Chart, What's New, and What to Expect — Emerson Medical maintenance semaglutide dose New Evidence

As part of our reporting on the safety of generic drugs and the track records of the factories that make them, were digging deeper into where your medication is coming from

High-dose GHRP-6: Moderate-high risk Why it's concerning: Significant appetite increase (can derail diet) Prolactin elevation (gynecomastia risk in sensitive individuals) Cortisol increase at high doses Water retention When it might be acceptable: Moderate doses (100-200mcg, not 300+mcg) Short-term use (8-12 weeks) If appetite increase isn't problematic Safer alternatives: Ipamorelin (no prolactin/cortisol increase) Lower GHRP-6 doses with careful monitoring Hexarelin: Higher risk than benefits justify Why it's problematic: Rapid desensitization (must cycle frequently) Cortisol and prolactin elevation Heart stress concerns Diminishing returns Limited use cases: Very short cycles (4 weeks maximum) Experienced users only With careful monitoring Better options: Ipamorelin for sustained results GHRP-2 for middle ground Synthetic growth hormone: Highest overall risk Why avoid: Complete shutdown of natural GH production Organ growth (hands, feet, jaw, internal organs) Insulin resistance Expensive Requires PCT (post-cycle therapy) Legal issues in most countries Only justified for: Medical growth hormone deficiency Under physician supervision Replacement doses, not supraphysiological Much safer alternatives: CJC-1295 + Ipamorelin stack Natural peptides that stimulate endogenous GH No shutdown, no PCT needed See peptides vs steroids and peptides vs SARMs for safety comparisons

They also note that weight regain has been reported with other weight loss methods, such as gastric bypass and vertical banded gastroplasty

The suppression nadir occurs during days 4-10 post-cessation when endogenous GH pulse amplitude drops 30-50% below baseline as the pituitary recalibrates after prolonged exogenous stimulation

doi: 10.1007/s10787-022-01017-8 123 KaurD